A clinical trial for the immunosuppression withdrawal for stable pediatric liver transplant recipients

Advances in immunosuppression and surgical care have improved short-term patient and graft survival for liver transplant recipients but left physicians and researchers with different challenges — maintaining the allograft function, while minimizing the long-term immune and non-immune complications related to immunosuppressive medications.

This is arguably most important for children who face a long lifespan and, consequently, a greater potential to develop significant end-organ damage.

The iWith clinical trial addresses this challenge by assessing the effectiveness and safety of immunosuppression withdrawal in a well-defined population of pediatric liver transplant recipients whose inherent immune status may predispose to operational tolerance.

CHOP’s Biesecker Pediatric Liver Center is an active participant in iWith research.